Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574
Recruiting
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/17/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/17/2025
Locations: Alabama Kidney Research, Alabaster, Alabama
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Register for Updates
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
NCT05966493
Recruiting
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/17/2025
Locations: Glaukos Investigative Site, Dothan, Alabama
Conditions: Persistent Corneal Epithelial Defect
Register for Updates
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595
Recruiting
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama
Conditions: Advanced or Metastatic Colorectal Cancer
Register for Updates
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552
Recruiting
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Hematological Malignancies
Register for Updates
Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
NCT04002882
Recruiting
Nutrition and body composition, the amount of muscle and fat in the body, has a role in overall health. This study wants to learn more about how nutrition and body composition affects health outcomes like glucose tolerance and lung function in patients with cystic fibrosis (CF) who are ages 16-30 years old. 60 adolescents and young adults with CF will be recruited, and 30 volunteers without cystic fibrosis. A total of 40 of these study participants with CF will be asked to return for annual stud... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/17/2025
Locations: University of Alabama at Birmingham (UAB)/Children's of Alabama, Birmingham, Alabama
Conditions: Cystic Fibrosis
Register for Updates
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043
Recruiting
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
NCT06899217
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: G & L Research, LLC, Foley, Alabama
Conditions: Idiopathic Gastroparesis
Register for Updates
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805
Recruiting
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Birmingham, Alabama
Conditions: HIV Infections
Register for Updates
CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR
NCT06560684
Recruiting
This is a Phase 2, multi-site, two-period, open label randomized crossover (Period 1 and 2) study. Participants are randomized 1:1 to one of two 8-week on-demand product sequences - TFV douche then oral F/TDF or oral F/TDF then TFV douche - with a 2 to 4-week washout period in between. Domains of safety, acceptability, adherence, and PK/PD (sub-study only) are assessed for each product.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Alabama CRS (Site ID# 31788), Birmingham, Alabama
Conditions: Tenofovir
Register for Updates
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443
Recruiting
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/16/2025
Locations: Allervie Clinical Research, Birmingham, Alabama
Conditions: Moderate to Severe Asthma
Register for Updates
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
NCT05692180
Recruiting
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/16/2025
Locations: Research Site, Mobile, Alabama
Conditions: Asthma
Register for Updates